Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine prospektive multizentrische klinische Studie zur Bewertung der Sicherheit und Wirksamkeit einer IOL mit einer Optik mit virtueller Apertur

14. September 2026 aktualisiert von: Z Optics, Inc.

Eine prospektive multizentrische klinische Studie zur Bewertung der Sicherheit und Wirksamkeit einer Intraokularlinse mit einer Optik mit virtueller Apertur

Cataracts are cloudy areas in the lens of the eye that can cause changes in vision. Symptoms of cataracts include cloudy or fuzzy vision and sensitivity to glare. Cataract extraction with Intraocular lens (IOL) implantation is the most commonly performed surgical procedure in the world.

Presbyopia affects almost everyone over the age of 50. With age, the natural crystalline lens loses its ability to change shape, or accommodate, to focus on near distances. Thus, individuals with excellent distance vision will still need to wear spectacles for near tasks such as reading, and intermediate tasks such as computer work.

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

The Z+ Virtual Aperture Optic IOL has been designed to perform similarly to monofocal IOL in that it corrects for distance vision but is also designed to provide a greater depth of focus. This greater depth of focus should improve near and intermediate visual acuities and thus reducing spectacle dependance. Therefore, it is expected that the Z+ Virtual Aperture Optic IOL will be a safe and efficient option for patients with presbyopia who desires spectacle independence after cataract surgery.

Studientyp

Interventionell

Einschreibung (Geschätzt)

60

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Coimbra, Portugal
      • Lisbon, Portugal
        • Noch keine Rekrutierung
        • Portugal Site 3
        • Kontakt:
          • Telefonnummer: +351 21 710 4400
      • Reinach, Schweiz

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

40 Jahre bis 75 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Adults, Age 40 to 75 years at the time of surgery, diagnosed with bilateral cataracts with planned cataract removal by phacoemulsification with a clear cornea incision and posterior chamber IOL implantation;
  2. Preoperative best-corrected distance visual acuity (BCDVA) worse than 20/30 Snellen;
  3. Clear intraocular media, other than cataract;
  4. Calculated lens power within the available range (available range of +16 D to +24 D);
  5. Preoperative keratometric astigmatism of less than 0.75 D in both operative eyes;
  6. Potential for postoperative BCDVA of 20/25 or better in each eye after cataract removal and IOL implantation;
  7. Able to comprehend and have signed a statement of informed consent;
  8. Availability, willingness, ability and sufficient cognitive awareness to comply with examination procedures and study visits;

Exclusion Criteria:

  1. Desire for monovision correction

  2. History of Dry Eye treatments/devices (example IPL, Lipiflow, iLux, Tear Care, Bruder Mask, True Tear) or any dry eye medications other than artificial tears (example, Restasis, Xiidra, Cequa, Klarity-C, generic cyclosporine/compounded cyclosporine)

  3. Active or recurrent anterior segment pathology (chronic uveitis, iritis, iridocyclitis, rubeosis iridis, Reiter's syndrome, etc.);

  4. Clinically significant corneal abnormalities or defects including corneal dystrophy (e.g., epithelial, stromal, or endothelial dystrophy), irregularity (including irregularity due to dry eye syndrome), inflammation or edema per the Investigator's expert medical opinion. Note: conditions including, but not limited to: keratitis, keratoconjunctivitis, keratouveitis, keratopathy, or keratectasia should be excluded;

  5. Previous corneal or intraocular surgery;

  6. Irregular corneal astigmatism; or regular corneal astigmatism greater than or equal to +/-0.75D;

  7. Inability to achieve stable keratometric readings for contact lens wearers;

    *The recommended time for discontinued wear of extended-wear or daily wear soft lenses is one week prior to surgery, one month for gas permeable and six months for PMMA lenses. No evidence of significant corneal warpage from contact lens use should be present on corneal topography and if the subject has been wearing a rigid gas permeable contact lens there should be two stable serial topographies at least 1 month following cessation of contact lens wear

  8. Higher-order Zernike corneal aberrations (3rd -order and above) RMS value greater than 1.0 um for the central 6-mm diameter area;

  9. Pupil dilation in scotopic conditions >5mm

  10. Use of systemic or ocular medications that may affect vision or likely to impact pupil dilation or iris structure;

  11. Pharmacologically dilated pupil size less than 6 mm in either eye;

  12. Pupil abnormalities;

  13. History of ocular trauma, prior refractive or other ocular surgery or subjects expected to require retinal laser treatment or other surgical intervention;

  14. Any disease or pathology, other than cataract, that (in the expert opinion of the Investigator) is expected to reduce the potential postoperative BCDVA. Note: Conditions including, but not limited to the following: amblyopia, clinically severe corneal dystrophy (e.g., epithelial, stromal, or endothelial dystrophy), diabetic retinopathy, extremely shallow anterior chamber, not due to swollen cataract, microphthalmos, previous retinal detachment, previous corneal transplant, recurrent severe anterior or posterior segment inflammation of unknown etiology, iris; neovascularization, uncontrolled glaucoma, aniridia, or optic nerve atrophy, or diagnosis of pseudoexfoliation;

  15. Neovascularization, uncontrolled glaucoma, aniridia, or optic nerve atrophy;

  16. Subjects who have profound sensitivity to glare at night with oncoming traffic headlights or subjects who are sensitive to fluorescent light flicker;

  17. Subjects who may reasonably be expected to require a SSI at any time during the study (other than YAG capsulotomy);

  18. Subject is pregnant, plans to become pregnant, is lactating or has another condition associated with hormonal fluctuation that could lead to refractive changes and dry eye. Females of childbearing age must have a negative pregnancy test at screening in order to be enrolled into the study.

  19. Concurrent participation or participation in any clinical trial up to 30 days prior to preoperative visit;

  20. Acute, chronic, or uncontrolled systemic or ocular disease or any illness that, in the opinion of the investigator, would increase the operative risk or confound the outcome(s) of the study (e.g., poorly-controlled diabetes);

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Z+ VAO IOL

FG-80030.1 hydrophobic

Subjects will undergo surgery to remove cataract (natural cloudy lens) via phacoemulsification implant the IOL Both eyes will be treated one month apart. Subjects will be followed up during 12 months

implant the IOL in both eyes. Both eyes will be treated one month apart. Subjects will be followed up during 12 months

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Binocular photopic uncorrected visual acuity
Zeitfenster: 6 months
  • Binocular photopic uncorrected visual acuity at 6-months at 4 meters (infinity): uncorrected distance visual acuity (UDVA).
  • Binocular photopic uncorrected visual acuity at 6-months at 4 meters (infinity) at 66 cm (intermediate): uncorrected intermediate visual acuity (UIVA).
  • Binocular photopic uncorrected visual acuity at 6-months at 4 meters (infinity) at 1.5 meters (intermediate walking visual acuity): uncorrected walking visual acuity (UWVA)
6 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Efficacy : Binocular defocus/depth of focus curve
Zeitfenster: 3 months

Binocular defocus/depth of focus curve under photopic conditions at the 3-month visit. Depth of Focus is calculated as the mean binocular diopters of range of focus where the visual acuity is 20/40 or better. The depth of focus will be measured at 66 cm, using the UIVA as the starting point. Defocus will be measured in 0.50D steps from +1.5D of positive defocus to -2.5D of negative defocus.

3 months
Efficacy : Uncorrected Visual Acuity
Zeitfenster: 6 months

3 meters (TV viewing distance): uncorrected TV visual acuity (UTVVA) at 6 months.

6 months
Efficacy : Visual Acuity
Zeitfenster: 1 month
  • VA under mesopic conditions at 1.5m using ETDRS charts.
  • VA under mesopic conditions at 66cm using ETDRS charts.
1 month
Efficacy : Continuous-objective visual assessment by Vivior defocus curves
Zeitfenster: 12 Months

Continuous-objective visual assessment: Measured with Vivior Visual Behavior monitor and assessed with the Vivior defocus curves to compare post-operative vs pre-operative visual requirements

12 Months
Efficacy : Patient questionnaire
Zeitfenster: 12 Months

Patient reported outcomes: Near Activity Visual Questionnaire (NAVQ)

Questions related to the difficulty of the patient to perform tasks at near distance. Evaluation is rated on a scale from 0 to 3 defined as follows :

0 : No difficulty

  1. : A little difficulty
  2. : Moderate difficulty
  3. : Extrement difficulty
12 Months
Safety - Best corrected visual acuity
Zeitfenster: 1 month

Loss of 10 letters or more of BCDVA when compared to Loss of 10 letters or more of BCDVA when compared to Preoperative or Postop Month 1.

1 month
Safety : Visual Acuity
Zeitfenster: 1 month
  • VA under mesopic conditions at 1.5 m.
  • VA under mesopic conditions at 66cm.
1 month
Safety : Percentage of patient with visual disturbances
Zeitfenster: 12 Months

Assessment of visual disturbances at 6-month visit using either the Glare/Halo simulator and/or an objective assessment of Visual Disturbance

12 Months
Safety : secondary surgical interventions
Zeitfenster: 12 Months

The cumulative rate of secondary surgical interventions (SSIs) related to the optical properties of the IOL

12 Months
Safety : Intraocular Pressure (IOP)
Zeitfenster: 12 Months

Intraocular Pressure (IOP)

12 Months
Safety : Slit Lamp Examination
Zeitfenster: 12 Months
  • Evaluation of Lens centration.
  • Evaluation of lens tilt.
  • Examination of capsule.
  • Examination of striae ratings.
12 Months
Safety : slit lamp observations
Zeitfenster: 12 Months

IOL Observations including Posterior Capsule Opacification

12 Months
Safety : Rate of Posterior Capsulotomy
Zeitfenster: 12 Months

Rate of Posterior Capsulotomy

12 Months
Safety : Slit lamp Fundus Visualization
Zeitfenster: 12 Months

Fundus Visualization

12 Months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

7. August 2025

Primärer Abschluss (Geschätzt)

1. August 2027

Studienabschluss (Geschätzt)

1. September 2027

Studienanmeldedaten

Zuerst eingereicht

3. Juli 2023

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

12. Juli 2023

Zuerst gepostet (Tatsächlich)

21. Juli 2023

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

18. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

14. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • VAO-IOL-004

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .